Pharmacy Benefit Manager Accountability · September 2026

The middlemen are on trial.

A consolidated view of every active federal and state action against the pharmacy benefit managers — Caremark, Express Scripts, OptumRx and the GoodRx pricing alliance. Each status, judge, allegation and filing is tagged with a plain-English explainer. Hover anything.

Last reviewed June 11, 2026 · Sources: FTC Legal Library, U.S. District Court (D.R.I.), JPML, NCPA & plaintiff firms.

Recent updates

Major federal proceedings running in parallel

PBM & pricing-platform defendants under tracking

40+

Independent-pharmacy plaintiffs consolidated in MDL 3148

$7B

Projected 10-yr patient savings cited in the ESI settlement

Real-time status grid

Where each defendant stands in each proceeding, right now. A cell is a verdict-at-a-glance — hover for the why.

Rows = defendants
Columns = proceedings

Active / Contested Negotiating / Stayed Settled Pending ruling Not named

Case dossiers

The full file on each proceeding — court, judge, defendants, the legal theory, the latest docket entries, and who’s saying what.

State & legislative front

The courts aren’t the only battlefield. States and Congress are rewriting the rules PBMs operate under.

Executive Summary

The FTC front is settling out — and the private price-fixing war takes center stage.

After two years of pressure, the pharmacy-benefit-manager model is being challenged on every front at once. In February 2026 the FTC won a landmark consent settlement with Express Scripts in the insulin rebating case (Docket 9437), finalized June 10, 2026. That deal cracked the wall — and Caremark and OptumRx followed: the FTC announced a Caremark settlement agreement on July 14 and published the proposed order in the Federal Register on Aug 5, with public comment closing Sept 4; OptumRx's proposed order is still pending. On June 30, the 8th Circuit dismissed the PBMs’ constitutional countersuit against the FTC by mutual agreement, closing out the last open thread in the federal case. The important nuance as of September: only Express Scripts is under a final, binding order — Caremark and OptumRx are at the proposed-order stage and have admitted no liability.

In parallel, every major PBM faces a private antitrust war: independent pharmacies allege that the GoodRx ISP let competitors fix the prices they pay pharmacies — a textbook Sherman Act §1 claim now consolidated before one judge in Rhode Island.

The throughline: regulators and pharmacies are attacking the same machinery — rebate-driven pricing and DIR-style fee clawbacks — from two directions.

i.All three have folded — but only one is bound. Express Scripts is under a final consent order. Caremark's proposed order finished its public comment period on Sept 4 and OptumRx's is still pending; neither is enforceable until the Commissioners vote. Treat coverage calling them "settled" carefully.
ii.The constitutional fight is over. The PBMs’ countersuit against the FTC was dismissed by the 8th Circuit on June 30 — mutually dropped now that all three have settled or proposed settlements.
iii.The pharmacy MDL is now the main event. MDL 3148 is the sole fully contested front. Briefing closed in May and Judge McElroy still hasn't ruled four months on — her decision determines whether the price-fixing theory reaches discovery.
iv.Watch arbitration. PBM contracts may force some pharmacies out of court — the single biggest threat to the class action.
v.The state front moved to the appellate courts. The 8th Circuit struck Arkansas's pharmacy network rules as ERISA-preempted (June 29), and the 2nd Circuit kept state opioid suits against the PBMs in federal court (Sept 2). Tennessee's ownership ban is the next test.
vi.For employers: settlements are forcing transparency and de-linked pricing into standard PBM contracts. The next renewal is the moment to demand it.